Better Education on Glomerular Disease: Improving Diagnosis and Treatment of C3 Glomerulopathy
Released On
December 15, 2022
Expires On
December 15, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Nephrology, Primary Care, Surgery
Topic(s)
Other
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Annenberg Center for Health Sciences at Eisenhower.
Supported by an educational grant from Novartis.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 contact hour
- CA-BRN — 1.0 contact hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
Nephrologists, nephrology physician associates / physician assistants and nurse practitioners, primary care physicians, pediatricians, surgeons who specialize in organ transplants, and other healthcare professionals who may be involved in diagnosis and treatment of patients with C3 glomerulopathy.
Program Overview
Nephrology specialists Carla Nester, MD, and Andrew Bomback, MD, delve into the rare and difficult-to-diagnose disease state of C3 glomerulopathy, a membranoproliferative form of glomerulonephritis. Recent guideline updates and recommended clinical management strategies for the treatment of glomerular disease are reviewed. In addition, the specific pathophysiology, clinical features and diagnosis of C3 glomerulopathy are discussed, as well as the global patient burden of disease and concomitant disease states caused by complement dysregulation. Insight into the historical management of C3 glomerulopathy and targeted therapies currently undergoing evaluation in late clinical trials are provided. Finally, patient resources, supportive measures and clinical perspective on the future of C3 glomerulopathy management are discussed by the faculty.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Discuss recent guideline recommendations on glomerular disease management
- Describe the epidemiology and pathophysiology of C3G
- Identify the appropriate imaging and testing for diagnosis of C3G
- Construct treatment plans for patients diagnosed with C3G
- Describe the safety and efficacy of targeted therapies undergoing late-phase clinical trial evaluation in patients with C3G
Faculty
Andrew S. Bomback, MD, MPH
Associate Professor of Medicine
Director of Clinical Research, Division of Nephrology
Columbia University Irving Medical Center
New York, New York
Carla M. Nester, MD, MSA
Jean E. Robillard MD Endowed Chair in Pediatric Nephrology
Director, Division of Pediatric Nephrology, Dialysis and Transplantation
Associate Director, Molecular Otolaryngology and Renal Research Laboratory
University of Iowa Stead Family Children’s Hospital
Iowa City, Iowa
Accreditation Statement
In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physicians
The Annenberg Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.0 ANCC contact hour.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.0 contact hour. To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Disclosures of Conflicts of Interest
It is the policy of the Annenberg Center to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relationships with ACCME-defined ineligible companies.
The Annenberg Center assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant financial relationships that are identified are mitigated by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
- Andrew S. Bomback, MD, MPH
- Consultant: Achillion, Alexion, Apellis, Catalyst, ChemoCentryx, Novartis, Silence, Visterra, Q32
- Carla M. Nester MD, MSA
- Advisory Board: Apellis, BioCryst, Novartis
- Data Monitoring Safety Board: Kira
- Research Support: Apellis, BioCryst, ChemoCentryx, Novartis, Retrophin
Additional content planners
The following have no significant relationship to disclose:
Lauren Schmidt, PharmD (Medical Writer)
Kam Newman, MD (Peer Reviewer)
Heather Jimenez, FNP-C (Nurse Reviewer)
Annenberg Center for Health Sciences
All staff at the Annenberg Center have no relevant financial relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Instructions for Participation and Credit
This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The faculty for this activity have disclosed that there will be discussion about the use of products for non-FDA approved applications.
Disclaimer
The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center for Health Sciences at Eisenhower disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.
Contact Information
For help or questions about this activity please contact Continuing Education:
ce@annenberg.net